Donate For Public and Patients Store Search

F058 - Advanced Management Strategies for Hidradenitis Suppurativa

Saturday, March 2; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Manage antibiotic and biologic treatment of hidradenitis suppurativa
  • Use office-based surgical and laser procedures in the care of hidradenitis patients
  • Determine the optimal combination of medical and surgical management of hidradenitis patients

Description

This session is directed toward an audience already familiar with the basic management of hidradenitis suppurativa. Medical management using a range of antibiotic and biologic agents will be a major focus. Procedural management using both lasers and traditional surgical procedures such as excision and unroofing in the office setting will be reviewed with the goal of preparing an audience of dermatologists to adopt surgical procedures in their practice. Case studies focusing on how to select the optimal treatment strategies in particular scenarios will also be described.

Disclosures

  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
  • Jemec, Gregor B.E., MD: AbbVie – A(H), I(Grants/Research Funding); Astion Pharma – C(H); Desitin Arzneimittel GmbH – Speaker/Faculty Education(NC); InflaRx GmbH – A(H), C(H), I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(NC); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); UCB – A(H);
  • Micheletti, Robert, MD: no financial relationships exist with commercial interests.
  • Prens, Errol P., MD, PhD: AbbVie – I(Grants/Research Funding), Speaker/Faculty Education(H); Celgene – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Regeneron – I(H);
  • Sayed, Christopher John, MD: AbbVie – A(Fees), I(Fees), SP(Fees); ChemoCentryx – I(Grants/Research Funding); GlaxoSmithKline – I(Fees); InflaRx – I(Grants/Research Funding); Novartis – I(Fees), SP(NC); Tioga Pharmaceuticals, Inc. – I(Fees); UCB – C(Fees), I(Grants/Research Funding);
Schedule
Saturday, March 2
1:00 PM
Dr. Jemec / Antibiotics in the management of HS
1:20 PM
Dr. Micheletti / Biologics in the management of HS
1:40 PM
Dr. Hamzavi / Lasers and lights in HS
2:00 PM
Dr. Jemec, Dr. Hamzavi, and Dr. Micheletti / Q&A and break
2:10 PM
Dr. Prens / Office-based surgery for HS
2:30 PM
Dr. Sayed / Case-based approaches for HS patients
2:50 PM
Dr. Sayed and Dr. Prens / Q&A and break
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 3:00 PM
  • Location
    Ballroom B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Christopher John Sayed, MD, FAAD
Speakers
  • Errol P. Prens, MD, PhD
  • Gregor B.E. Jemec, MD
  • Iltefat H. Hamzavi, MD, FAAD
  • Robert Micheletti, MD, FAAD - Handout